ReviewJournal of clinical medicine2022
Mechanical Thrombectomy for Acute Ischemic Stroke in Patients with Malignancy: A Systematic Review.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Clot composition analysis in ischemic stroke of cancer patients: a systematic review.BMC neurology · 2026Pooled it
- Plasma Metabolomics of Thrombectomy-Treated Patients Highlights Metabolic Pathways Underlying Disease and Recovery.CNS neuroscience & therapeutics · 2026Article
- Mechanical Thrombectomy in Patients with Malignancy: Comparable Procedural Success but Less Favorable Long-Term Outcomes.Brain sciences · 2026Article
- The Thrombectomy Dilemma in Stroke Patients With Active Cancer: To Treat or Not to Treat?Journal of stroke · 2026Review
- Endovascular Thrombectomy in Cancer-Related Stroke: Comparison of Thrombectomy Methods.Stroke (Hoboken, N.J.) · 2025Article
- Intravenous thrombolysis in the context of stroke and cancer.Journal of thrombosis and thrombolysis · 2025Review
- Endovascular treatment in ischemic stroke with active cancer: retrospective analysis of university stroke center data.Neurological research and practice · 2025Article
- Article
- Usefulness of Mechanical Thrombectomy in Patients with Cancer Who Developed Cerebral Infarction.Neurologia medico-chirurgica · 2024Article
- Post-Thrombectomy Subarachnoid Hemorrhage: Incidence, Predictors, Clinical Relevance, and Effect Modulators.Diagnostics (Basel, Switzerland) · 2024Article
- Long-term outcomes of mechanical thrombectomy in acute ischaemic stroke patients with concomitant malignancy.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2024Article
- Successful Recanalization and Neurological Restoration in Cancerous Embolic Cerebral Infarction via Endovascular Stent-Retriever Embolectomy.OncoTargets and therapy · 2024Article
- A Single-Center Experience of Mechanical Thrombectomy for Cancer-Associated Ischemic Stroke.Journal of neuroendovascular therapy · 2024Article
- Preprocedural D-Dimer Level as a Predictor of First-Pass Recanalization and Functional Outcome in Endovascular Treatment of Acute Ischemic Stroke.Journal of clinical medicine · 2023Article
- Editorial: New Advances in Cerebrovascular Disorders.Journal of clinical medicine · 2023Article
- Bridging the Gap in Cancer-Related Stroke Management: Update on Therapeutic and Preventive Approaches.International journal of molecular sciences · 2023Review
- Acute reperfusion treatment and secondary prevention of cancer-related stroke: comprehensive overview and proposal of clinical algorithm.Therapeutic advances in neurological disorders · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIschemic stroke is a common occurrence in patients with concomitant malignancy. Systemic thrombolysis is often contraindicated in these patients, and mechanical thrombectomy (MT) is the preferred method of intervention. This review aims to collect the available data on the safety and efficacy of MT in cancer patients (CPs).
methodsThe PubMed/MEDLINE and SCOPUS databases were systematically searched for studies assessing safety (mortality, intracranial hemorrhage) and efficacy (reperfusion, functional outcome) indices in CPs receiving MT. Potentially relevant parameters examined in solitary studies were also extracted (e.g., stroke recurrence, brain malignancy).
resultsA total of 18 retrospective studies of various methodologies and objectives were identified. Rates of in-hospital mortality, intracranial hemorrhage of any kind, reperfusion rates, and discharge condition did not seem to present any considerable differences between CPs and patients without cancer. On the contrary, 90-day mortality was higher and 90-day functional independence was lower in CPs. Three studies on cancer-related stroke (no other identifiable etiology and high D-dimer levels in the presence of active cancer) showed constant tendencies towards unfavorable conditions.
conclusionsPer the available evidence, MT appears to be a safe treatment option for CPs. It is still unclear whether the 90-day mortality and outcome rates are more heavily influenced by the malignancy and not the intervention itself, so MT can be considered in CPs with prospects of a good functional recovery, undertaking an individualized approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.